Imai H, Kawase T, Yoshida S, Mese T, Roh S, Fujita A, et al. Peripheral T cell profiling reveals downregulated exhaustion marker and increased diversity in lymphedema post-lymphatic venous anastomosis. iScience. 2023;26:106822 pubmed publisher

Zhong G, Wang Q, Wang Y, Guo Y, Xu M, Guan Y, et al. scRNA-seq reveals ATPIF1 activity in control of T cell antitumor activity. Oncoimmunology. 2022;11:2114740 pubmed publisher

Arasanz H, Bocanegra A, Morilla I, Fern xe1 ndez Irigoyen J, Mart xed nez Aguillo M, Teijeira L, et al. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer. Cancers (Basel). 2022;14: pubmed publisher

Qin L, Wang L, Zhang J, Zhou H, Yang Z, Wang Y, et al. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer. Sci Adv. 2022;8:eabn3774 pubmed publisher

Ando M, Kondo T, Tomisato W, Ito M, Shichino S, Srirat T, et al. Rejuvenating Effector/Exhausted CAR T Cells to Stem Cell Memory-Like CAR T Cells By Resting Them in the Presence of CXCL12 and the NOTCH Ligand. Cancer Res Commun. 2021;1:41-55 pubmed publisher

Edwards C, Sette A, Cox C, Di Fiore B, Wyre C, Sydoruk D, et al. The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. Br J Cancer. 2021;: pubmed publisher

Alenazy M, Saheb Sharif Askari F, Omair M, El Wetidy M, Omair M, Mitwalli H, et al. Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance. Sci Rep. 2021;11:5629 pubmed publisher

Tao L, Farooq M, Gao Y, Zhang L, Niu C, Ajmal I, et al. CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19+HLA-C1- Malignant B Cells While Sparing CD19+HLA-C1+ Healthy B Cells. Cancers (Basel). 2020;12: pubmed publisher

Zheng L, Ren L, Kouhi A, Khawli L, Hu P, Kaslow H, et al. A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models. Clin Cancer Res. 2020;26:3694-3706 pubmed publisher

Zuazo M, Arasanz H, Fernández Hinojal G, García Granda M, Gato M, Bocanegra A, et al. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. EMBO Mol Med. 2019;: pubmed publisher

Yeo L, Woodwyk A, Sood S, Lorenc A, Eichmann M, Pujol Autonell I, et al. Autoreactive T effector memory differentiation mirrors β cell function in type 1 diabetes. J Clin Invest. 2018;128:3460-3474 pubmed publisher